Researcher:
Yılmaz, Ebru

Profile Picture
ORCID

Job Title

PhD Student

First Name

Ebru

Last Name

Yılmaz

Name

Name Variants

Yılmaz, Ebru

Email Address

Birth Date

Filters

20211

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.0e58ec27-5ccc-48cc-a330-c37e8f6778f7

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    PublicationOpen Access
    IDH mutations in glioma: double-edged sword in clinical applications?
    (Multidisciplinary Digital Publishing Institute (MDPI), 2021) Kayabölen, Alişan; Yılmaz, Ebru; Önder, Tuğba Bağcı; Faculty Member; Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM); Graduate School of Health Sciences; School of Medicine; N/A; N/A; 184359
    Discovery of point mutations in the genes encoding isocitrate dehydrogenases (IDH) in gliomas about a decade ago has challenged our view of the role of metabolism in tumor progression and provided a new stratification strategy for malignant gliomas. IDH enzymes catalyze the conversion of isocitrate to alpha-ketoglutarate (alpha-KG), an intermediate in the citric acid cycle. Specific mutations in the genes encoding IDHs cause neomorphic enzymatic activity that produces D-2-hydroxyglutarate (2-HG) and result in the inhibition of alpha-KG-dependent enzymes such as histone and DNA demethylases. Thus, chromatin structure and gene expression profiles in IDH-mutant gliomas appear to be different from those in IDH-wildtype gliomas. IDH mutations are highly common in lower grade gliomas (LGG) and secondary glioblastomas, and they are among the earliest genetic events driving tumorigenesis. Therefore, inhibition of mutant IDH enzymes in LGGs is widely accepted as an attractive therapeutic strategy. On the other hand, the metabolic consequences derived from IDH mutations lead to selective vulnerabilities within tumor cells, making them more sensitive to several therapeutic interventions. Therefore, instead of shutting down mutant IDH enzymes, exploiting the selective vulnerabilities caused by them might be another attractive and promising strategy. Here, we review therapeutic options and summarize current preclinical and clinical studies on IDH-mutant gliomas.